Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA

Deadline:08 Jun 2026, 09:00 GMT-4

Tender information

SAM.gov

BETHESDA, United States

Type: Presolicitation
Procedure: Presolicitation
Ref. number: d5d41b4868e442a8b06dd1fd4a373f8c
NAICS: 51321

The MIB is conducting pre-clinical research on photoimmunotherapy (PIT), a targeted treatment approach that uses light activation to destroy specific cells. One area of this research focuses on IL2RA, a protein expressed…

on regulatory T cells (Tregs). These cells can reduce the immune system�s ability to respond effectively to cancer. The objective of this work is to selectively eliminate IL2RA-expressing Tregs in order to improve anti-cancer immune responses. To support this research, MIB uses a transgenic mouse s

train known as B-hIL2RA, which expresses the human form of IL2RA rather than the mouse form. Use of this model is essential because it enables evaluation of the same treatment materials, including antibodies, that are intended for future hu

Show all tender information

Documents

Show all important dates